secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0001193125-23-194625
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica closes $125M debt financing from OrbiMed; $50M funded, $75M tranched on revenue milestones
--------------------------------------------------------------------------------

- $50M borrowed at closing; up to $75M additional available in five tranches subject to YCANTH revenue thresholds.
- Five-year term loan matures July 2028; interest rate is one-month SOFR plus 8% (floor 4%).
- OrbiMed receives warrant for 518,551 shares at $6.0264 per share (10-year term).
- Proceeds support commercialization of YCANTH, FDA-approved July 21, 2023 for molluscum contagiosum.
- Cash runway extended into Q1 2025; company believes no additional equity financing needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523194625/0001193125-23-194625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523194625/d519666d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-194625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer